am 251 has been researched along with Facial Pain in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Facial Pain: Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almeida, RT | 1 |
| Romero, TR | 1 |
| Romero, MG | 1 |
| de Souza, GG | 1 |
| Perez, AC | 1 |
| Duarte, ID | 1 |
1 other study available for am 251 and Facial Pain
| Article | Year |
|---|---|
Endocannabinoid mechanism for orofacial antinociception induced by electroacupuncture in acupoint St36 in rats.
Topics: Acupuncture Points; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Dose-R | 2016 |